阿茲海默症市場：KOL 洞察

本報告考察了全球阿茲海默症市場，並提供了市場概述，包括已上市的治療方法、管道趨勢和未來前景。

目錄

執行摘要

目前與未來的治療演算法

研究目的

最近核准的治療方法

• 抗澱粉樣蛋白 BETA (A-BETA) 單株抗體 (mAb)
  • 主要見解摘要
  • Aduhelm（Aducanumab、Biogen/神經免疫療法）
  • Rekenbi（recanemab；BioArctic/Eisai/Biogen）

管道產品

• 抗澱粉樣蛋白 BETA (A-BETA) 單株抗體
• BETA澱粉樣蛋白抑制劑/GABA A 受體激動劑
• 勝肽水解酶抑制劑
• 毒蕈鹼受體調節劑/sigma-1受體激動劑
• 微絲蛋白調節劑
• 肝細胞生長因子刺激劑
• 毒蕈鹼 (M1/M4) 受體藥物
• 突觸核蛋白抑制劑/tau 蛋白抑制劑
• IL23、IL6抑制劑/MAPK3/MAPK1抑制劑/NF-KB抑制劑/TNF抑制劑
• 胰高血糖素樣勝肽1受體激動劑
• 5型環核甘酸磷酸二酯酶抑制劑
• 乙醯膽鹼酯酶抑制劑/菸鹼受體調節劑
• 5-HT1 5-羥色胺受體激動劑/褪黑素受體激動劑/5-羥色胺1D/2B受體激動劑

早期展望

• 主要見解摘要
  • ABBV 916（BETA 澱粉樣蛋白抑制劑；AbbVie）
  • ACI 24（抗 ABETA 疫苗，AC 免疫）
  • ACI 35.030（脂質體抗 pTau 疫苗；AC Immune/Janssen Pharmaceuticals）
  • AEF 0217（大麻素受體 CB1 拮抗劑；Aelis Farma）
  • AL-002（TREM2 蛋白刺激劑；Alector）
  • ALN APP（RNA 幹擾，Alnylam Pharmaceuticals）
  • AV 1959D（基於 DNA 的抗原決定位疫苗，Capo Therapeutics）
  • Beplanemab（tau 蛋白抑制劑；UCB Biopharma/Roche）
  • BIIB 080（IONIS-MAPTRX/反義 tau 蛋白抑制劑；Biogen/Ionis Pharmaceuticals）
  • Elcubragistat（單醯基甘油脂肪酶抑制劑；Abide Therapeutics/Lundbeck A/S）
  • Pepinemab（CD100 抗原抑制劑，Vaccinex）
  • Valoglutamstat；（麩醯胺酸肽環轉移酶抑制劑；Vivoryon Therapeutics）
  • Contraloid（BETA澱粉樣蛋白抑制劑；Priavoid）
  • PRX012（抗 A-BETA抗體，Prothena）
  • Semolinemab（抗 tau 抗體；AC Immune/Roche）
  • Teltomotide（端粒酶勝肽疫苗；Pharmaxa/KAEL-GemVax/Samsung Pharm）

附錄

While KOLs say BioArctic/Biogen/Eisai's Leqembi is set to dominate AD therapy, what are the dosing, cost and reimbursement challenges that could impact takeup? Eli Lilly's next-generation late-stage anti-amyloid therapy donanemab is eagerly anticipated, but what clinical advantages and challenges do experts identify, and how might it impact Leqembi? KOLs critically assess the prospects of launched and pipeline therapies.

In addition to the full report, licensed users can access the following KOL Bulletins via the Attachments area.

Key questions answered:

• Biogen's Aduhelm was seen as a trailblazer in AD therapy but has failed to live up to expectations - how do KOLs assess the failure?
• How might Eli Lilly's remternetug offer better patient convenience and the possibility of home-based administration?
• How do KOLs assess the potential of Roche's innovative Brainshuttle approach for trontinemab?
• Tau remains an attractive target, so why are KOLs sceptical about the prospects for Annovis Bio's Posiphen and TauRx's LMTX?
• How do KOLs assess pipeline therapies which do not target amyloid and tau pathways, such as AlphaCognition's Alpha 1062, AriBio's AR 1001, Karuna Therapeutics' KarXT and BioVie's NE3107?
• Why is KOL opinion split on the prospects for Alzheon's niche pipeline therapy valiltramiprosate?

Key brands covered in this report:

Table of Contents

Executive summary (6)

Current and future treatment algorithm

Research objectives (2)

Recently approved therapies (19)

• Anti-amyloid beta (A-Beta) monoclonal antibodies (mAbs) (19)
  • Key insights summary (2)
  • Aduhelm (aducanumab; Biogen/Neurimmune Therapeutics) (1)
  • Leqembi (lecanemab; BioArctic/Eisai/Biogen) (16)

Pipeline products (104)

• Anti-amyloid beta (A-Beta) mAbs (19)
  • Key insights summary (2)
  • LY 3002813 (donanemab; Eli Lilly & Co.) (1)
  • LY-3372993 (remternetug; Eli Lilly & Co.) (1)
  • RG-6102 (trontinemab; Roche) (15)
• Amyloid beta-protein inhibitors/GABA A receptor agonists (7)
  • ALZ 801 (valiltramiprosate; BELLUS Health/FB Health/Alzheon) (7)
• Peptide hydrolase inhibitors (6)
  • COR-388 (atuzaginstat; Lighthouse Pharmaceuticals) (6)
• Muscarinic receptor modulators/Sigma-1 receptor agonists (6)
  • Blarcamesine (Anavex Life Sciences) (6)
• Microfilament protein modulators (6)
  • Filora (simufilam; Cassava Sciences) (6)
• Hepatocyte growth factor stimulants (8)
  • Fosgonimeton (Athira Pharma) (8)
• Muscarinic (M1/M4) receptor agents (7)
  • KarXT (trospium chloride/xanomeline; Karuna Therapeutics [BMS]) (7)
• Synuclein inhibitors/Tau protein inhibitors (10)
  • Key insights summary (2)
  • LMTX (hydromethylthionine mesylate; TauRx Pharmaceuticals) (1)
  • Posiphen (buntanetap; Annovis Bio) (7)
• IL23, IL6 inhibitors/MAPK3/MAPK1 inhibitors/NF-kB inhibitors/TNF inhibitors (9)
  • NE3107 (BioVie) (9)
• Glucagon-like peptide 1 receptor agonists (8)
  • Rybelsus (semaglutide oral; Novo Nordisk) (8)
• Type 5 cyclic nucleotide phosphodiesterase inhibitors (4)
  • AR 1001 (AriBio) (4)
• Acetylcholinesterase inhibitors/Nicotinic receptor modulators (7)
  • Alpha 1062 (benzgalantamine; AlphaCognition) (7)
• 5-HT1 serotonin receptor agonists/Melatonin receptor agonists/Serotonin 1D/2B receptor agonists (7)
  • Neu-P11 (piromelatine; Neurim Pharmaceuticals) (7)

Early-stage prospects (21)

• Key insights summary (21)
  • ABBV 916 (amyloid beta-protein inhibitor; AbbVie) (1)
  • ACI 24 (anti-Abeta vaccine; AC Immune) (1)
  • ACI 35.030 (liposomal anti-pTau vaccine; AC Immune/ Janssen Pharmaceuticals) (1)
  • AEF 0217 (cannabinoid receptor CB1 antagonist; Aelis Farma (1)
  • AL-002 (TREM2 protein-stimulant; Alector) (1)
  • ALN APP (RNA interference; Alnylam Pharmaceuticals) (1)
  • AV 1959D (DNA based epitope vaccine; Capo Therapeutics) (1)
  • Bepranemab (Tau protein inhibitor; UCB Biopharma/Roche) (1)
  • BIIB 080 (IONIS-MAPTRX/antisense Tau protein inhibitor; Biogen/Ionis Pharmaceuticals) (1)
  • Elcubragistat (monoacylglycerol lipase inhibitor; Abide Therapeutics/Lundbeck A/S) (1)
  • Pepinemab (CD100 antigen inhibitors; Vaccinex) (1)
  • Varoglutamstat; (glutaminyl-peptide cyclotransferase inhibitor; Vivoryon Therapeutics) (1)
  • Contraloid (amyloid beta-protein inhibitor; Priavoid) (1)
  • PRX012 (anti-A-Beta antibody; Prothena) (1)
  • Semorinemab (anti-tau antibody; AC Immune/Roche) (1)
  • Tertomotide (telomerase peptide vaccine; Pharmexa/KAEL-GemVax/Samsung Pharm) (4)

Appendix (5)

• KOL details (5)
  • KOLs from North America (1)
  • KOLs from Europe (3)